STAAR Surgical Company - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 27, 2002, and the nine-month period ended on the same date. STAAR Surgical Company develops, manufactures, and distributes medical devices for minimally invasive ophthalmic surgery, primarily intraocular lenses (IOLs), implantable contact lenses (ICLs), and phacoemulsification systems. The company operates globally with manufacturing sites in the United States and Switzerland.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 27, 2002 | 9 Months Ended Sep 27, 2002 |
|---|---|---|
| Total Revenues | $11,201 | $35,020 |
| Gross Profit | $5,620 | $17,356 |
| Gross Margin | 50.2% | 49.6% |
| Operating Loss | $(1,698) | $(6,442) |
| Net Loss | $(2,144) | $(7,050) |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.41) |
| Cash and Cash Equivalents | $663 | $663 (Ending Balance) |
| Notes Payable (Current) | $6,356 | $6,356 (Ending Balance) |
| Net Working Capital | $8,936 | $8,936 (Ending Balance) |
Note: Cash flow from operating activities for the nine months ended September 27, 2002, was $2 (positive), compared to a use of $2,786 in the prior year period.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 7.8% in the quarter and 8.0% for the nine months compared to the prior year. This was primarily driven by a 15% (quarter) and 16% (nine-month) decline in IOL sales due to performance issues with lens insertion systems and lower average selling prices.
- Product Mix Shift: Weakness in IOL sales was partially offset by significant growth in other products: STAARVisc II (+146% Q/Q, +351% 9M/9M), Aquaflow (+30% Q/Q, +101% 9M/9M), and ICLs (+33% 9M/9M).
- Cost of Sales: Cost of sales as a percentage of revenue increased to 49.8% (quarter) and 50.4% (nine months) from 45.0% and 42.3% respectively in the prior year. This was attributed to higher unit costs of IOL inventory manufactured during low-volume periods and a shift in sales mix.
- Restructuring Charges: The company recorded $1.2 million in subsidiary closure charges (South Africa and Sweden) in the second quarter and $230,000 in employee separation costs in the third quarter.
- Debt Reduction: Notes payable decreased from $8,216 (Dec 2001) to $6,356 (Sep 2002). The company utilized $2.0 million of released restricted cash to pay down debt.
Guidance, Outlook, Risks, and Contingencies
Management Commentary & Outlook: Management expects gross profit on IOLs to improve as higher-cost inventory is sold. The company is focused on a restructuring plan to restore profitability, though there is no assurance of success. The company relies on external financing and believes it has sufficient cash to fund operations, though this is not certain.
Debt Covenants & Liquidity: The company has a history of failing to meet financial covenants (operating income, cash flow, tangible net worth) with its domestic lender. Agreements were renegotiated in July and October 2002, requiring monthly principal reductions. The company has pledged substantially all assets as collateral. Failure to meet future covenants could lead to foreclosure.
Deferred Tax Assets: The company holds deferred tax assets of approximately $9.3 million but maintains a valuation allowance of $8.95 million due to a history of losses. Realization depends on generating sufficient future U.S. taxable income.
Legal Proceedings:
- John R. Wolf: Former CEO filed wrongful termination and stock option claims; the company has filed counterclaims regarding loans.
- Derivative Suit: A stockholder derivative suit alleges breach of fiduciary duty by directors regarding loans and service fees. The company filed a motion to dismiss in October 2002.
Risks: Key risks include product recalls (specifically IOL insertion systems), intense competition from larger firms (Alcon, Bausch & Lomb), regulatory approval delays, and foreign currency fluctuations.
Investor Verification Checklist
- Covenant Compliance: Verify the company's ability to meet the strict monthly principal reduction requirements and financial covenants of its renegotiated domestic loan agreement.
- IOL Product Performance: Assess the resolution of the lens insertion system performance issues and their impact on future IOL sales volume and pricing.
- Deferred Tax Realization: Monitor the company's ability to generate U.S. taxable income to realize the $9.3 million in deferred tax assets without further valuation allowances.
- Liquidity Position: Review the current ratio (1.5:1) and cash burn rate given the reliance on external financing and the reduction of credit facilities.
- Legal Exposure: Track the status of the John R. Wolf litigation and the stockholder derivative suit for potential financial impact.